Is there a cure for systemic lupus erythematosus?

Lupus

Volumn 22, Issue 5, 2013, Pages 417-421

  Rosario, C ^a   Seguro, L ^b   Vasconcelos, C ^c   Shoenfeld, Y ^d  

^a Hospital de Pedro Hispano   (Portugal)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital Santo Antonio   (Portugal)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

cure; prolonged remission; sustained remission; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOTHERAPY; DISEASE DURATION; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; REMISSION INDUCTION; TIME FACTORS;

EID: 84875926396     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313479839     Document Type: Review

References (60)

1. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004 ; 34: 501-537
2. Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf: Mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004 ; 3: 423-453
3. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol. 1987 ; 14: 223-226
4. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 ; 82: 299-308
5. Katz U, Zandman-Goddard G. Drug-induced lupus: An update. Autoimmun Rev. 2010 ; 10: 46-50
6. Campuzano-Maya G. Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter. 2007 ; 2: 265-273
7. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: A systematic review. Blood. 2009 ; 113: 1231-1240
8. De Luis DA, Varela C, De La Calle H, et al. Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis. J Clin Gastroenterol. 1998 ; 26: 259-263
9. Franceschi F, Satta MA, Mentella MC, et al. Helicobacter pylori infection in patients with Hashimoto's thyroiditis. Helicobacter. 2004 ; 9: 369-369
10. Aragona P, Magazzù G, Macchia G, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren's syndrome. J Rheumatol. 1999 ; 26: 1306-1311
11. Sorrentino D, Faller G, DeVita S, et al. Helicobacter pylori associated antigastric autoantibodies: Role in Sjögren's syndrome gastritis. Helicobacter. 2004 ; 9: 46-53
12. Avci O, Ellidokuz E, Simsek I, Buyukgebiz B, Gunes AT. Helicobacter pylori and Behcet's disease. Dermatology. 1999 ; 199: 140-143
13. Ali M, Whitehead M. Clearance of chronic psoriasis after eradication therapy for Helicobacter pylori infection. J Eur Acad Dermatol Venereol. 2008 ; 22: 753-754
14. Martin Hübner A, Tenbaum SP. Complete remission of palmoplantar psoriasis through Helicobacter pylori eradication: A case report. Clin Exp Dermatol. 2008 ; 33: 339-340
15. Kikuchi T, Kobayashi T, Yamashita T, Ohashi K, Sakamaki H, Akiyama H. Eight-year follow-up of patients with immune thrombocytopenic purpura related to H. pylori infection. Platelets. 2011 ; 22: 61-64
16. Mubarak A, Houwen RH, Wolters VM. Celiac disease: An overview from pathophysiology to treatment. Minerva Pediatr. 2012 ; 64: 271-287
17. Uramoto KM, Michet CJ, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999 ; 42: 46-50
18. Halberg P, Alsbjorn B, Balslov JT, et al. Systemic lupus erythematosus: follow-up study of 148 patients: I. Classification, clinical and laboratory findings, course and outcome. Clin Rheumatol. 1987 ; 6: 13-21
19. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?. J Rheumatol. 2005 ; 32: 1706-1708
20. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: An update. Ann Acad Med Singapore. 2007 ; 36: 115-122
21. Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol. 2005 ; 23: S120 - S132
22. Luijten KM, Tekstra J, Bijlsma JW, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev. 2012 ; 11: 326-329
23. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005 ; 19: 685-708
24. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol. 2000 ; 27: 377-379
25. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 ; 32: 1467-1472
26. Tozman ECS, Urowitz MB, Gladman DD. Prolonged complete remission in previously severe SLE. Ann Rheum Dis. 1982 ; 41: 39-40
27. Drenkard C, Villa AR, Garcia-Padilla C, Pérez-Vázquez ME, Alarcón-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore). 1996 ; 75: 88-98
28. Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, Pujol R. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology (Oxford). 1999 ; 38: 724-727
29. Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol. 1985 ; 12: 916-918
30. Schneider M. Response and remission criteria for clinical trials in lupus: What can we learn from other diseases?. Lupus. 1999 ; 8: 627-631
31. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: Frequency and outcome. J Rheumatol. 2010 ; 37: 1822-1827
32. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: A discordance between clinical and serologic features. Am J Med. 1979 ; 66: 210-215
33. Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol. 1994 ; 21: 2239-2241
34. Yadin O, Sarov B, Naggan L, Slor H, Shoenfeld Y. Natural autoantibodies in the serum of healthy women - a five-year follow-up. Clin Exp Immunol. 1989 ; 75: 402-406
35. Mittal G, Balakrishna C, Mangat G, Joshi VR. "Sustained remission" in a case of SLE following megadose cyclophosphamide. Lupus. 1999 ; 8: 77-80
36. Rossi E, Catania G, Truini M, Ravetti GL, Grassia L, Marmont AM. Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE. Clin Exp Rheumatol. 2011 ; 29: 555-559
37. Moroni G, Greloni GC, Ponticelli C. Late recurrence of lupus nephritis after long-term clinical remission. Nephrol Dial Transplant. 2001 ; 16: 849-852
38. Burt RK, Testori A, Craig R, Cohen B, Suffit R, Barr W. Hematopoietic stem cell transplantation for autoimmune diseases: What have we learned?. J Autoimmun. 2008 ; 30: 116-120
39. Marmont AM. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Clin Dev Immunol. 2012 ; 2012: 380391-380391
40. Illei GG, Cervera R, Burt RK, et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011 ; 70: 2071-2074
41. Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010 ; 10: 3-7
42. Muñoz LE, Janko C, Schulze C, et al. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev. 2010 ; 10: 38-42
43. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011 ; 365: 2110-2121
44. Mok CC. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs. 2010 ; 15: 53-70
45. Bezalel S, Asher I, Elbirt D, Sthoeger ZM. Novel biological treatments for systemic lupus erythematosus: Current and future modalities. Isr Med Assoc J. 2012 ; 14: 508-514
46. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011 ; 11: 56-60
47. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006 ; 54: 2970-2982
48. Van Vollenhoven RF. Rituximab - shadow, illusion or light?. Autoimmun Rev. 2012 ; 11: 563-567
49. Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 2001 ; 44: 432-441
50. Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial. Arthritis Rheum. 2008 ; 58: 3873-3883
51. Mozes E, Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev. 2010 ; 10: 22-26
52. Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT. Moving towards a cure: Blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med. 2011 ; 269: 36-44
53. Jayne D, Passweg J. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004 ; 13: 168-176
54. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010 ; 95: 284-292
55. Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: A retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011 ; 118: 1693-1698
56. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used. Blood. 2007 ; 109: 2643-2648
57. Bohgaki T, Atsumi T, Koike T. Multiple autoimmune diseases after autologous stem-cell transplantation. N Engl J Med. 2007 ; 357: 2734-2736
58. McKendry RJ, Huebsch L, Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation: A case report with a 13-year follow-up. Arthritis Rheum. 1996 ; 39: 1246-1253
59. Tapprich C, Fenk R, Schneider P, Bernhardt A, Haas R, Kobbe G. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant. 2003 ; 32: 629-631
60. Marmont AM, Gualandi F, Van Lint MT, Bacigalupo A. Refractory Evans' syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus autoimmunity effect. Bone Marrow Transplant. 2003 ; 31: 399-402